Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

ACSL4: Biomarker, Mediator and Target in Quadruple Negative Breast Cancer

News

June 14, 2023
PRESS RELEASE: On June 12, 2023, a new review paper was published in Oncotarget, entitled, “ACSL4: biomarker, mediator and target in quadruple negative breast cancer.” continue reading »

LP-284 Targets Non-Hodgkin’s Lymphoma and DNA Damage Repair Deficiency

News

June 12, 2023
PRESS RELEASE: On June 12, 2023, a new research paper was published in Oncotarget, entitled, “LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.” continue reading »

Targeting the Src N-Terminal Regulatory Element in Cancer

News

June 9, 2023
PRESS RELEASE: On May 19, 2023, Oncotarget published a new research perspective: “Targeting the Src N-terminal regulatory element in cancer.” continue reading »

Value of Chemotherapy Post Immunotherapy in Stage IV Non-Small Cell Lung Cancer

News

June 7, 2023
PRESS RELEASE: On May 26, 2023, a new research paper was published in Oncotarget, entitled, “Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC).” continue reading »

BORIS Gene Mutation and Expression: Link to Breast Cancer Progression

News

June 5, 2023
PRESS RELEASE: On May 26, 2023, a new research paper was published in Oncotarget, entitled, “Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression.” continue reading »